Here’s a look at the drugs that may shape 2017, compliments of FirstWord Pharma. It’s a list of some of the products I agree are likely to dominate industry news… Read more »
Corporate , Pharmaceuticals Acadia Pharmaceuticals , AstraZeneca PLC , Billy Dunn , Center for Drug Evaluation and Research , Chantix , Chrono Therapeutics , Clovis Oncology , CTL019 , Docetaxel , Dupilumab , Dupixent , Durvalumab , Epidiolex , Eylea , FirstWord Pharma , Forbes , Herceptin , Juno Therapeutics Inc. , Keytruda , Kite Pharma , KTE-C19 , Luke Timmerman , Lynparza , National Institutes of Health , Niraparib , Novartis AG , Nuplazid , Nusinersen , Ocrelizumab , Ocrevus , Opdivo , Perjeta , Pertuzumab , Praluent , Prescription Drug User Fee Act , Regeneron Pharmaceuticals Inc. , Repatha , Roche Holding AG , Rubraca , Sanofi SA , Second Genome , Seres Therapeutics , Spinraza , Synlogic , Tecentriq , Trastuzumab , Vendanta Biosciences , Verubecestat , Zyban
